Language:
Instant News and Commentaries
2026-04-22
15:30
Microsoft: Microsoft 365 E7 Frontier Suite to Be Launched in HK in May

Microsoft (MSFT.US) announced that, as part of its 'Frontier Transformation' initiative, Microsoft 365 E7 Frontier Suite, as a Wave 3 of Microsoft Copilot, will be officially launched in Hong Kong on 1 May.

Microsoft 365 E7 integrates Microsoft 365 Copilot, Work IQ and Agent 365, while featuring enterprise-grade security, identity management and AI agent governance capabilities.

AIA (01299.HK) is leveraging Microsoft’s AI platform to implement a comprehensive agentic AI strategy across its operations, encompassing AI agent-powered product training, sales object management & knowledge access, automated claims processing and customer self-service.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
14:32
BofAS Keeps Rating at Buy on Apple (AAPL.US), Expects Smooth Leadership Transition

Apple (AAPL.US) announced a major leadership transition after market closed on Monday (20th), BofA Securities issued a research report saying. Tim Cook will become Executive Chairman of the Board, while John Ternus, currently senior vice president of Hardware Engineering, will succeed as CEO, effective 1 September 2026.

The broker believed that the move signals positively for Apple's long-term vision, as Ternus has worked at Apple for more than 20 years and previously led hardware development across iPhone, iPad, Mac, Apple Watch, AirPods and Vision Pro.

BofA Securities viewed Cook's continuation as Chairman and his ongoing engagement with global policymakers as a positive sign for a smooth transition.

2027 will mark the 20th anniversary of iPhone and could be a big product year, BofA Securities added. The broker estimated the transition to proceed smoothly, similar to Apple's previous senior leadership changes. Therefore, BofA Securities kept rating at Buy on Apple, with a target price of US$325.
~


AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
14:17
BofAS Keeps Buy on Tesla; Mkt Eyeing New Product R&D Pipeline

Tesla (TSLA.US) is set to release its 1Q26 results this week, and investors are likely to lay their eyes on the progress of the company's robotaxi deployment, BofA Securities wrote in its report.

Last Saturday, BofA Securities expressed that it was encouraged by Tesla's announcement that it had expanded its robotaxi services to Dallas and Houston, bringing the total number of deployed cities to four, a step closer to its target of reaching nine cities in 1H26.

BofA Securities also predicts investor attention to go to the progress in scaling up production of the Optimus humanoid robot, which forms a key component of Tesla's USD20 billion capital expenditure plan for this year. While the broker doesn't expect Optimus to make a meaningful contribution in the near term, it still sees substantial long-term potential.

Tesla's rating remains Buy, alongside a target price of USD460. BofA Securities believes the company is in the early stages of monetizing its autonomous driving capabilities.
~



AAStocks Financial News
Web Site: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
09:26
【2026 ASCO】亞盛醫藥多項研究入選,其中三項獲快速口頭報告

美國馬裡蘭州羅克維爾市和中國蘇州2026年4月22日 /美通社/ -- 致力於在腫瘤等領域開發創新藥物的領先的生物醫藥企業——亞盛醫藥(納斯達克代碼:AAPG;香港聯交所代碼:6855)宣布,公司三個重點品種的六項臨床研究入選2026年美國臨床腫瘤學會(ASCO)年會,其中三項獲快速口頭報告。這三個重點品種分別為中國首個獲批上市的第三代BCR-ABL抑制劑奧雷巴替尼(商品名:耐立克®)、中國首個獲批上市的國產原創Bcl-2選擇性抑制劑利沙托克拉(商品名:利生妥®)和MDM2-p53抑制劑Alrizomadlin(APG-115)。

一年一度的ASCO年會是全球腫瘤領域最重要、最權威的學術交流盛會,將展示當前國際最前沿的臨床腫瘤學科研成果和腫瘤治療技術。本屆ASCO年會將於5月29日至6月2日(美國當地時間)在芝加哥McCormick會議中心以線上線下結合的形式舉辦。

亞盛醫藥首席醫學官翟一帆博士表示:「這將是亞盛醫藥連續第九年亮相ASCO年會,很高興能夠又一次站在這一國際頂尖學術舞台展示公司的全球創新與研發實力。今年,公司在研品種有多項研究入選,其中三項研究獲快速口頭報告,再次印證了國際學術界對公司原研品種臨床價值的高度認可。我們期待在會議期間為大家分享更為詳實的數據,並繼續加速全球臨床開發進程,早日為患者帶來更多治療選擇。」

亞盛醫藥將在本屆ASCO年會展示的臨床研究進展包括:

快速口頭報告

Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)
奧雷巴替尼(HQP1351)聯合貝林妥歐單抗治療淋系急變期慢性髓細胞白血病(CML-LBP)或費城染色體陽性B細胞前體急性淋巴細胞白血病(Ph+ BCP-ALL)患者
摘要編號:6513
展示形式:快速口頭報告
分會場標題:血液系統惡性腫瘤——白血病、骨髓增生異常綜合征及同種異體移植(Hematologic Malignancies—Leukemia, MDS, and Allotransplant)
報告時間:
2026年5月30日 13:15–14:45(美國中部時間)
2026年5月31日 凌晨2:15–3:45(北京時間)
第一作者:Elias Jabbour, MD,美國德克薩斯大學MD安德森癌症中心白血病科

Updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML)
奧雷巴替尼(HQP1351)二線治療慢性期慢性髓細胞白血病(CP-CML)患者的最新療效和安全性數據
摘要編號:6510
展示形式:快速口頭報告
分會場標題:血液系統惡性腫瘤——白血病、骨髓增生異常綜合征及同種異體移植(Hematologic Malignancies—Leukemia, MDS, and Allotransplant)
報告時間:
2026年5月30日 13:15–14:45(美國中部時間)
2026年5月31日 凌晨2:15–3:45(北京時間)
第一作者:黎緯明教授,華中科技大學同濟醫學院附屬協和醫院血液科

Alrizomadlin (APG-115) alone or in combination with Lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)
AlrizomadlinAPG-115)單藥或聯合利沙托克拉(APG-2575)治療復發/轉移性橫紋肌肉瘤(RMS)或其他軟組織肉瘤(STSs)兒童患者
摘要編號:10012
展示形式:快速口頭報告
分會場標題:兒童腫瘤II(Pediatric Oncology II)
報告時間:
2026年5月30日 8:00–9:30(美國中部時間)
2026年5月30日 21:00–22:30(北京時間)
第一作者:張翼鷟教授,中山大學腫瘤防治中心兒童腫瘤科,華南腫瘤學國家重點實驗室,腫瘤醫學協同創新中心

壁報展示

Updated clinical and translational results of Olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient tumors
奧雷巴替尼(HQP1351)治療琥珀酸脫氫酶缺陷型(SDH-)腫瘤患者的最新臨床和轉化研究結果
摘要編號:11539
展示形式:壁報展示
分會場標題:肉瘤(Sarcoma)
報告時間:
2026年6月1日 13:30–16:30(美國中部時間)
2026年6月2日 凌晨2:30–5:30(北京時間)
第一作者:邱海波教授,中山大學腫瘤防治中心,華南腫瘤學國家重點實驗室,腫瘤醫學協同創新中心

A phase 3 study of Olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress
奧雷巴替尼(HQP1351)治療慢性期慢性髓細胞白血病患者的III期臨床研究:正在進行中的POLARIS-2試驗
摘要編號:TPS6608
展示形式:壁報展示
分會場標題:血液系統惡性腫瘤——白血病、骨髓增生異常綜合征及同種異體移植(Hematologic Malignancies—Leukemia, MDS, and Allotransplant)
報告時間:
2026年6月1日 9:00–12:00(美國中部時間)
2026年6月1日 22:00–次日凌晨1:00(北京時間)
第一作者:Elias Jabbour, MD,美國德克薩斯大學MD安德森癌症中心白血病科

A global multicenter, open-label, randomized, phase 3 registrational study of Lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): GLORA trial in progress
利沙托克拉(APG-2575)治療既往經治慢性淋巴細胞白血病/小淋巴細胞淋巴瘤(CLL/SLL)患者的全球多中心、開放性、隨機、III期注冊臨床研究:正在進行中的GLORA試驗
摘要編號:TPS7101
展示形式:壁報展示
分會場標題:血液系統惡性腫瘤——淋巴瘤和慢性淋巴細胞白血病(Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia)
報告時間:
2026年6月1日 9:00–12:00(美國中部時間)
2026年6月1日 22:00–次日凌晨1:00(北京時間)
第一作者:Matthew Steven Davids, MD,美國丹娜法伯癌症研究院

關於亞盛醫藥

亞盛醫藥(納斯達克代碼:AAPG;香港聯交所代碼:6855)是一家綜合性的全球生物醫藥企業,致力於研發、生產和商業化創新藥,以解決腫瘤領域全球患者尚未滿足的臨床需求。公司已建立豐富的創新藥產品管線,包括抑制Bcl-2和 MDM2-p53 等細胞凋亡通路關鍵蛋白的抑制劑、新一代針對癌症治療中出現的激酶突變體的抑制劑以及蛋白降解劑。

公司核心品種耐立克®是中國首個獲批上市的第三代BCR-ABL抑制劑,已獲批用於治療伴有T315I突變的慢性髓細胞白血病慢性期(CML-CP)和加速期(CML-AP)患者,以及對一代和二代TKI耐藥和/或不耐受的CML-CP成年患者。該藥物所有獲批適應症均已被納入中國國家醫保藥品目錄(NRDL)。目前,亞盛醫藥正在開展耐立克®三項全球注冊III期臨床研究,分別為:獲美國FDA和歐洲EMA許可的評估耐立克®治療新診斷費城染色體陽性急性淋巴細胞白血病(Ph+ ALL)患者POLARIS-1研究;獲美國FDA和歐洲EMA許可的評估耐立克®治療經治CML-CP成年患者的POLARIS-2研究;評估耐立克®治療SDH-缺陷型GIST患者的POLARIS-3研究。

公司另一重磅品種利生妥®是一款用於治療多種血液系統惡性腫瘤的新型Bcl-2抑制劑。利生妥®已獲中國國家藥品監督管理局(NMPA)批准,用於治療既往至少接受過一種包括布魯頓酪氨酸激酶(BTK)抑制劑在內的系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤(CLL/SLL)患者。目前,亞盛醫藥正在開展利生妥®四項全球注冊III期臨床研究,分別為:獲美國FDA和歐洲MEA許可的評估利生妥®聯合BTK抑制劑治療既往接受BTK抑制劑治療超過12個月且應答不佳的CLL/SLL患者的GLORA研究;評估利生妥®一線治療初治CLL/SLL患者的GLORA-2研究;評估利生妥®一線治療新診斷老年或不耐受的AML患者的GLORA-3研究;以及獲美國FDA和歐洲EMA許可的評估利生妥®一線治療新診斷中高危MDS患者的GLORA-4研究。

憑借強大的研發能力,亞盛醫藥已在全球范圍內進行知識產權布局,並與武田、阿斯利康、默沙東、輝瑞、信達等眾多領先的生物制藥公司達成全球合作,同時與丹娜法伯癌症研究院、梅奧醫學中心、美國國家癌症研究所和密西根大學等學術機構建立研發合作關系。如需了解更多信息,請訪問 https://ascentage.com/

前瞻性聲明

本新聞稿包含根據美國《1995年私人證券訴訟改革法案》,以及經修訂的《1933年證券法》第27A條和《1934年證券交易法》第21E條所界定的前瞻性陳述。除歷史事實陳述外,本新聞稿中的所有內容均可能構成前瞻性陳述,包括亞盛醫藥對未來事件、經營成果或財務狀況所發表的意見、預期、信念、計劃、目標、假設或預測。

這些前瞻性陳述受到諸多風險和不確定性的影響,具體內容已在亞盛醫藥向美國證券交易委員會(SEC)提交的文件中詳細說明,包括2025年1月21日提交的經修訂的F-1表格注冊說明書和2025年4月16日提交的20-F表格中的「風險因素」和「關於前瞻性聲明的警示聲明」章節、2019年10月16日提交的首次發行上市招股書中的「前瞻性聲明」、「風險因素」章節,以及我們不時向SEC或HKEX提交的其他文件。這些因素可能導致實際業績、運營水平、經營成果或成就與前瞻性陳述中明示或暗示的信息存在重大差異。本前瞻性聲明中的陳述不構成公司管理層的利潤預測。

因此,該等前瞻性陳述不應被視為對未來事件的預測。本新聞稿中的前瞻性陳述僅基於亞盛醫藥當前對未來發展及其潛在影響的預期和判斷,且僅代表截至陳述發表之日的觀點。無論出現新信息、未來事件或其他情況,亞盛醫藥均無義務更新或修訂任何前瞻性陳述。

Information Provided by PR Newswire [Disclaimer]
08:59
Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting

CHENGDU, China, April 22, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 29 to June 2. In this meeting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) will present results from three clinical studies, including data from its TROP2 ADC sacituzumab tirumotecan (sac-TMT, 佳泰莱®), next-generation selective RET inhibitor lunbotinib fumarate (A400/EP0031, 宁泰莱®[1]) and novel ADC SKB500. The abstracts for these studies will be published on the ASCO official website on May 21, 2026, local time.

Detailed information on the studies selected for 2026 ASCO is as follows:

Title: Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC): Results from the randomized, controlled phase III OptiTROP-Lung05 study
Presentation Type: Oral
Abstract Number: 8506
Session Date and Time: May 29, 3:12 PM-3:24 PM CDT | Lung Cancer-Non-Small Cell Metastatic

Title: Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC)
Presentation Type: Oral
Abstract Number: 8505
Session Date and Time: May 29, 2:36 PM-2:48 PM CDT | Lung Cancer-Non-Small Cell Metastatic

Title: An open-label, first-in-human study of SKB500 in patients with locally advanced or metastatic solid tumors
Presentation Type: Rapid oral
Abstract Number: 3011
Session Date and Time: June 2, 9:57 AM-10:03 AM CDT | Molecularly Targeted Agents and Tumor Biology

About sac-TMT

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with the anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative topoisomerase I inhibitor payload in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, four indications for sac-TMT have been approved and marketed in China for: 1) unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting);2) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy; 3) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; 4) unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) BC who have received prior ET and at least one line of chemotherapy in advanced setting. The first two indications above have been included in China's National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinically meaningful benefits to a greater number of patients with BC and NSCLC. Additionally, sac-TMT has been granted six Breakthrough Therapy Designations (BTDs) by the NMPA.

Sac-TMT is the world's first TROP2 ADC drug approved for marketing in lung cancer. As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD is evaluating 17 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About A400/EP0031

A400/EP0031 novel next-generation selective RET inhibitor for NSCLC, medullary thyroid cancer (MTC) and other solid tumors with a high prevalence of RET alterations. The NDA of A400/EP0031 has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of adult patients with RET-fusion positive locally advanced or metastatic NSCLC. The Company is also conducting a Phase Ib/II clinical study in China for the treatment of RET-positive solid tumors.

In March 2021, the Company granted Ellipses Pharma Limited, a U.K.-based international oncology drug development company, an exclusive license to develop, manufacture and commercialize this agent outside Greater China and certain Asian countries. In April 2024, A400/EP0031 was cleared by the Food and Drug Administration (FDA) to progress into a Phase II clinical trial (NCT05443126) which is currently recruiting in the United States, United Kingdom, Europe and United Arab Emirates, where it is being evaluated as a monotherapy and in combination with chemotherapy in RET fusion positive NSCLC.

About SKB500

SKB500, a novel, proprietary ADC developed via the OptiDC™ platform, is designed to leverage specific target biology through a validated target combined with a differentiated payload-linker strategy. In preclinical investigations, SKB500 demonstrated a favorable therapeutic window with robust efficacy and manageable safety profiles across multiple advanced solid tumors.

Currently, a Phase II exploratory study of SKB500 in combination with immunotherapy with or without chemotherapy as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) is ongoing in China.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.

[1] Trade name to be approved by NMPA

 

Information Provided by PR Newswire [Disclaimer]
08:28
2026 ASCO | 科倫博泰3項研究成果入選2026美國臨床腫瘤學會年會口頭彙報

成都2026年4月22日 /美通社/ -- 2026年美國臨床腫瘤學會(ASCO)年會將於529日至62日在美國芝加哥舉行。四川科倫博泰生物醫藥股份有限公司(「科倫博泰」或「公司」,6990.HK)將在本次大會公佈TROP2 ADC蘆康沙妥珠單抗(sac-TMT,佳泰萊®)、下一代選擇性RET抑制劑富馬酸侖博替尼(A400/EP0031,寧泰萊®[1])以及新型ADC SKB500的三項臨床研究結果,相關研究摘要全文將於當地時間2026年5月21日發佈在 ASCO 官方網站上。

2026 ASCO展示的臨床研究成果具體包括:

標題:蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗對比帕博利珠單抗一線治療PD-L1陽性晚期非小細胞肺癌(NSCLC):隨機、對照III期研究(OptiTROP-Lung05)結果
展示形式:口頭報告
摘要#:8506
會議日期和時間當地時間5月29日15:12-15:24 | 肺癌-轉移性非小細胞

標題:下一代選擇性RET抑制劑(SRI)富馬酸侖博替尼(A400/EP0031)用於治療晚期RET融合陽性非小細胞肺癌(NSCLC)患者的關鍵II期研究的療效與安全性
展示形式:口頭報告
摘要#:8505
會議日期和時間當地時間5月29日14:36-14:48 | 肺癌-轉移性非小細胞

標題:一項評估SKB500治療局部晚期或轉移性實體瘤患者的開放標籤、首次人體研究
展示形式:快速口頭報告
摘要#:3011
會議日期和時間當地時間6月2日9:57-10:03 | 分子靶向藥物與腫瘤生物學

關於蘆康沙妥珠單抗(sac-TMT)(佳泰萊®)
作為公司的核心產品,蘆康沙妥珠單抗(sac-TMT)是一款公司擁有自主智慧財產權的新型TROP2 ADC,針對NSCLC、乳腺癌(BC)、胃癌(GC)、婦科腫瘤及泌尿生殖系統腫瘤等晚期實體瘤。蘆康沙妥珠單抗(sac-TMT)採用獨特雙功能連接子開發而成。該連接子一方面通過與抗TROP2單抗沙妥珠單抗形成不可逆結合,另一方面在溶酶體中可從貝洛替康衍生物拓撲異構酶I抑制劑載荷pH敏感裂解,從而最大限度將有效載荷遞送至腫瘤細胞,藥物抗體比(DAR)達到7.4。蘆康沙妥珠單抗(sac-TMT)通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面的TROP2,其後被腫瘤細胞內吞併於細胞內釋放有效載荷KL610023。KL610023作為拓撲異構酶I抑制劑,可誘導腫瘤細胞DNA損傷,進而導致細胞週期阻滯及細胞凋亡。此外,其亦於腫瘤微環境中釋放KL610023。鑒於KL610023具有細胞膜滲透性,其可實現旁觀者效應,即殺死鄰近的腫瘤細胞。

於2022年5月,公司授予默沙東(美國新澤西州羅威市默克公司的商號)在大中華區(包括中國內地、香港、澳門及臺灣)以外的所有地區開發、使用、製造及商業化蘆康沙妥珠單抗(sac-TMT)的獨家權利。

截至目前,蘆康沙妥珠單抗(sac-TMT)的4項適應症已於中國獲批上市,分別用於:1)既往至少接受過2種系統治療(其中至少1種治療針對晚期或轉移性階段)的不可切除的局部晚期或轉移性TNBC;2)經EGFR-TKI和含鉑化療治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC;3)經EGFR-TKI治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC;4)既往接受過內分泌治療且在晚期疾病階段接受過至少一線化療的不可切除或轉移性的HR+/HER2- (IHC 0、IHC 1+或IHC 2+/ISH-) BC;其中前2項適應症已經被納入醫保範圍,將為更多乳腺癌和非小細胞肺癌患者帶來臨床意義上的獲益。此外,蘆康沙妥珠單抗(sac-TMT)已獲國家藥品監督管理局(NMPA)授予6項突破性療法認定(BTD)。

蘆康沙妥珠單抗(sac-TMT)是全球首個在肺癌適應症獲批上市的TROP2 ADC藥物。目前,科倫博泰已在中國開展9項註冊性臨床研究。默沙東已佈局17項正在進行的蘆康沙妥珠單抗(sac-TMT)作為單藥療法或聯合帕博利珠單抗或其他抗癌藥物用於多種類型癌症的全球性III期臨床研究(這些研究由默沙東申辦並主導)。

關於富馬酸侖博替尼(A400/EP0031)(寧泰萊®[1] )
A400/EP0031是一款新型下一代選擇性RET抑制劑,開發用於治療NSCLC、甲狀腺髓樣瘤(MTC)以及其他RET變異的實體瘤。A400/EP0031用於治療RET融合陽性的局部晚期或轉移性NSCLC成人患者的新藥上市申請(NDA)已獲中國國家藥品監督管理局藥品評審中心(CDE)受理。公司亦在中國進行一項其用於治療RET+實體瘤的Ib/II期臨床研究。

2021年3月,本公司向總部設在英國的國際腫瘤藥物開發公司Ellipses Pharma Limited授出在大中華區及部分亞洲國家之外開發、製造及商業化此藥物的獨家授權。2024年4月,A400/EP0031獲美國食品藥品監督管理局(FDA)批准進入II期臨床研究(NCT05443126),目前正在美國、英國、歐盟和阿聯酋入組患者,評估該藥物作為單藥及聯合化療在RET融合陽性NSCLC中的療效。

關於SKB500
SKB500是一款由公司針對靶點生物學特點,利用OptiDC™平臺技術研發的具有自主智慧財產權的新型ADC藥物,其採用了經驗證靶點與差異化的有效載荷-連接子策略。在前期研究中,SKB500顯示出良好的療效和安全窗,擬用於治療多種晚期實體瘤。目前,SKB500聯合免疫加與不加化療一線治療廣泛期小細胞肺癌(ES-SCLC)的聯合用藥探索II期研究正在中國進行中。

關於科倫博泰
四川科倫博泰生物醫藥股份有限公司(簡稱「科倫博泰」,股票代碼:6990.HK)是科倫藥業控股子公司,專注于創新生物技術藥物及小分子藥物的研發、生產、商業化及國際合作。公司圍繞全球和中國未滿足的臨床需求,重點佈局腫瘤、自身免疫和代謝等重大疾病領域,建設國際化藥物研發與產業化平臺,致力於成為在創新藥物領域國際領先的企業。公司目前擁有30余個重點創新藥項目,其中4個項目8個適應症已獲批上市,1個專案處於NDA階段,10餘個專案正處於臨床階段。公司成功構建了享譽國際的專有ADC及新型偶聯藥物平臺OptiDC™,已有2個ADC項目5個適應症獲批上市,多個ADC或新型偶聯藥物產品處於臨床或臨床前研究階段。

[1] 商品名待NMPA批准

 

Information Provided by PR Newswire [Disclaimer]
08:00
Innovent to Present New Clinical Data of IBI363(PD-1/IL-2α-biased bispecific fusion protein) at the 2026 ASCO Annual Meeting

SAN FRANCISCO and SUZHOU, China, April 22, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that clinical data for its first-in-class IBI363 (PD-1/IL-2α-biased bispecific fusion protein) * as well as TYVYT® (sintilimab injection)** will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 to June 2, 2026, in Chicago, Illinois, U.S.

Dr. Hui Zhou, Chief R&D Officer (Oncology) of Innovent, stated: "We are excited to announce that at the 2026 ASCO Annual Meeting, we will present new PoC data of IBI363 in NSCLC, across both IO-resistant and first-line settings. With robust PoC data for IO-resistant NSCLC now in hand, we are moving IBI363 into MRCT pivotal development, an important step toward tackling a major global unmet medical need. At the same time, we are encouraged by the promising dose optimization data in first-line NSCLC, and we look forward to continued maturation of PoC full data to inform our next steps. Innovent will continue to push the boundaries of cancer care, as we are dedicated to delivering physicians and patients more innovative, effective, and life-saving treatment options."

Abstracts of IBI363(PD-1/IL-2α-biased bispecific fusion protein)

1.  Presentation Title: IBI363 (TAK-928) plus chemotherapy as first line (1L) treatment for advanced non-small cell lung cancer (NSCLC).
Abstract Number: 8586
Session Type: Poster
Session Title: Lung Cancer/Non-Small Cell Metastatic
Session Date & Time: May 31, 2026 9:00 AM-12:00 PM CDT
Presenter: Dr. Haiyan Tu, Guangdong Provincial People's Hospital

2.  Presentation Title: First-in-class PD-1/IL-2α-bias bispecific antibody IBI363 (TAK-928) in patients (pts) with advanced immunotherapy-resistant non-small cell lung cancer (NSCLC): updated results from a phase I study.
Abstract Number: 2618
Session Type: Poster
Session Title: Developmental Therapeutics/Immunotherapy
Session Date & Time: May 30, 2026 1:30 PM-4:30 PM CDT
Presenter: Dr. Jianya Zhou, First Affiliated Hospital of Zhejiang University School of Medicine

3.  Presentation Title: Randomized phase 3 study (MarsLight-11) evaluating IBI363 (TAK-928) versus docetaxel in patients (pts) with squamous non-small cell lung cancer (sqNSCLC) after prior chemotherapy (chemo) and immunotherapy (IO).
Abstract Number: TPS8673
Session Type: Poster
Session Title: Lung Cancer/Non-Small Cell Metastatic
Session Date & Time: May 31, 2026 9:00 AM-12:00 PM CDT
Presenter: Dr. Roy S. Herbst, Yale School of Medicine

Abstracts of TYVYT®(sintilimab)

1.  Presentation Title: Adjuvant sintilimab plus bevacizumab following curative resection of spontaneously ruptured hepatocellular carcinoma: A prospective exploratory phase II study (CLEAR-2)
Abstract Number: TPS4254
Session Type: Poster
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Session Date & Time: May 30, 2026, 9:00 AM-12:00 PM CDT
Presenter: Dr. Yongjun Chen, Ruijin Hospital, Shanghai Jiaotong University School of Medicine

2.  Presentation Title: Neoadjuvant chemoradiotherapy with or without PD-1 blockade in pMMR/MSS low rectal cancer patients (CHOICE II): A multi-center, open-label, randomized controlled trial.
Abstract Number: 3640
Session Type: Poster
Session Title: Gastrointestinal Cancer—Colorectal and Anal
Session Date & Time: May 30, 2026, 9:00 AM-12:00 PM CDT
Presenter: Dr. Wei Zhang, Changhai Hospital

3.  Presentation Title: Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced Hepatocellular Carcinoma (aHCC): A Randomized, Open-label, Controlled, Multicenter Phase III Clinical Study 
Abstract Number: 4148
Session Type: Poster
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Session Date & Time: May 30, 2026, 9:00 AM-12:00 PM CDT
Presenter: Dr. Jia Fan, Zhongshan Hospital, Fudan University

4.  Presentation Title: CONCEPT (combination of cetuximab plus fruquintinib treatment ± immunotherapy): A multicenter, randomized, open-label phase II trial in first-line pMMR RAS/BRAF wild-type unresectable metastatic colorectal cancer.
Abstract Number: TPS3680
Session Type: Poster
Session Title: Gastrointestinal Cancer—Colorectal and Anal
Session Date & Time: May 30, 2026, 9:00 AM-12:00 PM CDT
Presenter: Dr. Yue Liu, The Second Affiliated Hospital of Zhejiang University School of Medicine.

5.  Presentation Title: Long-term survival and biomarker analysis of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial. 
Abstract Number: 3610
Session Type: Poster
Session Title: Gastrointestinal Cancer—Colorectal and Anal
Session Date & Time: May 30, 2026 9:00 AM-12:00 PM CDT
Presenter: Dr. Xiao Weiwei, Sun Yat-sen University Cancer Center

6.  Presentation Title: Larynx preservation via chemotherapy-free neoadjuvant sintilimab-cetuximab-SBRT and response-adapted treatment in locally advanced laryngeal cancer: A phase II, single-arm clinical trial (The NeoVOICE study).
Abstract Number: 6095
Session Type: Poster
Session Title: Head and Neck Cancer
Session Date & Time: May 30, 2026 1:30 PM-4:30 PM CDT
Presenter: Dr. Song Ming, Sun Yat-sen University Cancer Center

7.  Presentation Title: Pathological complete response and ctDNA analyses in SCIENCE: Results from a randomized, phase III trial of neoadjuvant chemotherapy plus sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy in resectable locally advanced esophageal squamous cell carcinoma.
Abstract Number: LBA4082
Session Type: Poster
Session Title: Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary
Session Date & Time: May 30, 2026 9:00 AM-12:00 PM CDT
Presenter: Dr. Xuefeng Leng, Sichuan Cancer Hospital

8.  Presentation Title: Sintilimab (PD-1 antibody) Plus Gemcitabine and Docetaxel (GT) as First-line or Later-line Therapy in Patients with Advanced Epithelioid Sarcoma: A Prospective, Multicenter, Single-arm, Phase II Clinical Study.
Abstract Number: 11574
Session Type: Poster
Session Title: Sarcoma
Session Date & Time: June 1, 2026 1:30 PM-4:30 PM CDT
Presenter: Dr. Xiaowei Zhang, Fudan University Shanghai Cancer Center

9.  Presentation Title: Sintilimab plus Anlotinib and Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma: A Prospective, Phase II Clinical Trial.
Abstract Number: 8050
Session Type: Poster
Session Title: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Session Date & Time: May 31, 2026 9:00 AM-12:00 PM CDT
Presenter: Dr. Jianchun Duan, Cancer Hospital, Chinese Academy of Medical Sciences

*Innovent entered into a license and collaboration agreement with Takeda for co-development and co-commercialization of IBI363 (Takeda R&D code: TAK-928). Please refer to the announcement for more information.

**Abstracts of TYVYT ®(sintilimab) are from investigator-initiated clinical trials (IIT), except for abstract #4148.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 18 products in the market. It has 5 assets in Phase III or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement: (1)Innovent does not recommend the use of any unapproved drug (s)/indication (s).

2Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company.

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

Information Provided by PR Newswire [Disclaimer]
04:12
Uncertainty Over US-Iran Talks Sends 3 Major US Stock Indices Tumbling; DJIA Ends Down 293 pts

Amid investor concerns that the US and Iran may fail to reach a peace agreement before Wednesday's ceasefire deadline, US equities headed south following early gains on Tuesday. The DJIA ended the day down 293 points or 0.6% at 49,149. The S&P 500 declined 45 points or 0.6% to close at 7,064. The Nasdaq dropped 144 points or 0.6%, closing at 24,259.

UnitedHealth (UNH.US) crossed the finish line up 7%. It delivered forecast-beating results for 1Q26 and raised earnings guidance. Amazon (AMZN.US) inched 0.7% higher. It announced plans to invest up to an additional USD25 billion in AI company Anthropic. 3M (MMM.US) receded 2% post-results. It maintained its full-year earnings guidance unchanged.
~



AAStocks Financial News
Web Site: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
02:41
CATL Unveils Six Major Innovations: Multi-Chemistry Systems to Redefine New Energy Mobility Experience

BEIJING, April 22, 2026 /PRNewswire/ -- CATL today hosted its Super Technology Day in Beijing, unveiling third-generation Shenxing Superfast Charging Battery, third-generation Qilin Battery, Qilin Condensed Battery, second-generation Freevoy Super Hybrid Battery, Naxtra Sodium-ion Battery and a fully integrated supercharging and battery-swapping solution. These innovations are designed to address diverse mobility needs across different usage scenarios.

Gao Huan, CTO of CATL China Car Business
Gao Huan, CTO of CATL China Car Business

At the event, Dr. Wu Kai, Chief Scientist of CATL, systematically elaborated on the respective strengths, limitations, and development pathways of different chemistries. He noted that LFP is nearing its theoretical energy density limit, making it better suited for a technology roadmap centered on extreme fast charging to achieve optimal balance. NCM's high energy density keeps it at the forefront of global competition — underscoring that energy density remains the core metric for leadership. Sodium-ion batteries offer broad potential for extreme temperatures and energy storage applications. Whether from the perspective of differentiated consumer needs, or from the viewpoints of energy security and social development, the lithium-ion battery industry must pursue coordinated development across multiple chemical systems.

Wu Kai, Chief Scientist of CATL
Wu Kai, Chief Scientist of CATL

Robin Zeng, Chairman and CEO of CATL, emphasized at the conference that industrial innovation must be driven by a rigorous scientific spirit. For Chinese technology to go global, it relies not just on speed and scale, but on the quality of innovation, the ability to validate, and the credibility of the brand.

Robin Zeng, Chairman and CEO of CATL
Robin Zeng, Chairman and CEO of CATL

Third-Generation Shenxing Superfast Charging Battery: Making Superfast Charging and Ultra-Long Lifespan No Longer a Trade-Off

From an electrochemical standpoint, boosting charge rates while protecting battery lifespan hinges on one primary factor: temperature rise, not trickle current. As the Arrhenius equation shows, a 10°C increase in battery temperature can roughly double the rate of internal side reactions—an effect that can significantly shorten cycle life.

The third-generation Shenxing Superfast Charging Battery addresses heat generation and dissipation through three major measures: reduced heat production during operation, stronger thermal propagation, and higher precision control. As a result, after 1,000 complete cycles, the battery's capacity retention remains above 90%, achieving an optimal balance between extreme superfast charging and ultra-long service life.

The latest third-generation Shenxing Superfast Charging Battery has reached what is claimed to be the industry's strongest capability: an equivalent 10C and a peak 15C charging rate. Charging from 10% to 35% SOC (State of Charge) takes just 1 minute; from 10% to 80% SOC takes 3 minutes and 44 seconds; and from 10% to 98% SOC takes 6 minutes and 27 seconds. Even at −30°C in extreme cold conditions, charging from 20% to 98% SOC takes about 9 minutes.

In addition, by combining battery self-heating technology with a fully integrated supercharging and battery-swapping network, the system is designed to enable low-temperature superfast charging that is not limited by charging piles—offering both fast charging and battery swapping.

Third Generation Shenxing Superfast Charging Battery
Third Generation Shenxing Superfast Charging Battery

Third-generation Qilin Battery: Lighter, Stronger, More Premium, Redefining EV Excellence

Historically, achieving long range in premium EVs with LFP batteries has relied on simply adding more capacity — an approach that inevitably compromises vehicle lightweighting.

The third-generation Qilin Battery is designed for premium long-range EVs, achieving a cell energy density of 280 Wh/kg and enabling 1,000 km range while supporting 10C superfast charging.

The battery delivers 3 MW peak power, doubling the output of the second-generation Qilin track battery which competed on the Nürburgring (1,330 kW).

The entire battery pack weighs only 625 kg. Compared with equivalent LFP systems, this represents a weight reduction of 255 kg and space savings of 112 litres. The lightweighting metrics deliver exceptionally significant benefits:

  • Energy consumption per 100 km decreases by more than 6%, saving approximately 0.78 kWh per 100 km. Across a fleet of one million vehicles travelling 20,000 km annually, this equates to 156 million kWh in electricity savings and a reduction of 78,500 tonnes of CO₂ emissions.
  • Performance and safety improvements include a 0.6–second reduction in 0–100 km/h acceleration, a 12% shorter overtaking risk window, an 8% higher moose test speed, a 6.5% lower body roll angle, a 15–25% gain in obstacle avoidance capability, and approximately 1.44 metres shorter braking distance.
  • Durability is enhanced, with chassis component life extended by 40% and tyre life by over 30%, increasing replacement intervals by at least 10,000 km. The 112 litres of space saved can increase cabin headroom by at least 18 mm.

Building on the national standard for NP (No Thermal Propagation), safety is strengthened through "thermal-electrical separation", with each cell incorporating an independent sealed exhaust channel to isolate thermal events and prevent propagation, ensuring "heat takes the heat path, electricity takes the electrical path". 

Third Generation Qilin Battery
Third Generation Qilin Battery

Qilin Condensed Battery: Aviation-Grade Technology Applied to Passenger Vehicles for the First Time

The Qilin Condensed Battery applies aviation-grade technology to passenger vehicles for the first time, achieving 350 Wh/kg cell energy density and 760 Wh/L volumetric energy density — setting a new record for mass-produced batteries. This enables 1,500 km range for sedans and over 1,000 km for large SUVs, with pack weight controlled within 650 kg.

The condensed battery features a high-nickel cathode and low-expansion silicon-carbon anode, boosting energy density by 50 Wh/kg. Its first-ever aviation-grade titanium alloy case reduced thickness by 60% and weight by 30%, while tripling unit strength and delivering an additional 20 Wh/kg in energy density.

The technology builds on CATL's electric aviation programme, where 500 Wh/kg systems have completed maiden flight validation on 4-tonne aircraft, with further validation underway on aircraft exceeding 8 tonnes.

Replacing liquid electrolyte with a condensed system eliminates risks associated with leakage and combustion, achieving "no liquid to leak, no liquid to ignite". At the same time, CATL has adopted a new composite current collector that acts as a fast self-fusing fuse in extreme cases of internal short circuits.

Qilin Condensed Battery
Qilin Condensed Battery

Second-generation Freevoy Super Hybrid Battery: Bringing Hybrids into the 600 km Pure Electric Era

The second-generation Freevoy Super Hybrid Battery extends all-electric range to up to 600 km and standardises 10C superfast charging. It pioneers a "super hybrid technology" that integrates LFP and NCM materials through gradient-uniform mixing, with the olivine crystal structure of LFP serving as the core backbone, enabling a uniform hybrid of LFP and NCM materials at the powder particle level.

This achieves an energy density of 230 Wh/kg and increases range by over 15% without increasing pack weight compared with single LFP systems. This enables full coverage from mainstream family use to high-end, all-round hybrid scenarios, delivering optimal solutions across diverse applications.

The LFP version delivers up to 500 km pure electric range, enabling a "once-a-week charging" experience for daily commuting. The NCM version further extends pure electric range beyond 600 km, with total vehicle range exceeding 2,000 km, enabling a seamless dual-use experience for both daily electric driving and long-distance travel.

The system delivers 1.5 MW of instantaneous power at full charge and maintains 1.2 MW at 20% SOC, addressing power degradation in low-charge conditions. In off-road scenarios requiring over 350 kW output, the system provides more than three times the required power, ensuring consistent performance even at low charge levels.

Safety features include a reinforced bottom coating capable of withstanding 1,500 joules of impact energy (ten times the national standard) and waterproof sealing that allows continuous immersion in 2 metres of water for over 200 hours without performance degradation.

Second Generation Freevoy Super Hybrid Battery
Second Generation Freevoy Super Hybrid Battery

Naxtra Sodium-ion Battery: Achieving GWh-scale Sodium-ion Industrialisation

The Naxtra Sodium-ion Battery marks CATL's transition from laboratory breakthrough to large-scale manufacturing. By systematically overcoming hundreds of engineering challenges, CATL has achieved GWh-level industrialisation.

In 2026, CATL successfully addressed four key industry bottlenecks for sodium-ion mass production—extreme water control, gas generation in hard carbon, aluminium foil adhesion, and self-forming anode systems—paving the way for reliable, large-scale deployment. The Naxtra Sodium-ion Battery is set to enter full-scale mass production by the end of 2026.

Naxtra Sodium-ion Battery
Naxtra Sodium-ion Battery

Integrated Supercharging and Battery-swapping Network: A Unified Replenishment Architecture

CATL also introduced an integrated supercharging and battery-swapping network, designed as a unified system rather than separate solutions, built on three complementary pillars—home charging, public charging, and battery swapping—to define the optimal energy replenishment ecosystem. All passenger vehicle "Choco-Swap" and heavy truck "QIJI" swapping stations will be equipped with Shenxing supercharging systems, enabling true charge–swap synergy, where each station serves both as a battery-swapping node and a high-power charging hub.

The integrated charge–swap stations feature shared compact substations and charging modules, reducing energy conversion steps and lowering overall power loss by more than 13 percentage points compared with conventional storage-equipped charging stations. In emergency scenarios, station batteries can discharge directly to charging piles, driving equipment utilization rate above 85%. This enables a service capacity of 3× per parking space compared with conventional storage-equipped charging stations, while the fixed investment cost of the supercharging segment is reduced to only one-fifth of comparable systems.

CATL launched the Choco-Swap #26 battery, featuring an 800V high-voltage architecture. The first release includes a 75 kWh version, with higher-capacity variants to follow, fully compatible with B- to C-segment 800V vehicles. With this launch, the Choco-Swap system will extend its coverage to a complete vehicle matrix from A0 to C-segment models.

In terms of network deployment, CATL plans to build 4,000 integrated charge–swap stations by the end of 2026, covering nearly 190 cities and a nationwide highway network spanning 12 vertical and 11 horizontal corridors. To date, the Choco-Swap network has already built 1,470 stations across 99 cities, with scaling continuing to accelerate.

Together with automakers and energy partners, CATL will co-develop a "charge–swap sharing network" based on technology sharing, seamless connectivity, and joint investment. Initial partners include Changan, Chery, GAC, Seres, SAIC-GM-Wuling, and BAIC, with a target of building over 100,000 shared energy replenishment facilities by the end of 2028.

Yang Jun, General Manager of CATL's Battery Swapping Business
Yang Jun, General Manager of CATL's Battery Swapping Business

Advancing full-scenario energy solutions

From five battery products covering the full material spectrum to an integrated supercharging and battery-swapping network, CATL has established a complete value chain from battery products to infrastructure.

CATL will continue to invest in advanced research, large-scale manufacturing and ecosystem collaboration to accelerate the transition from single-point innovation to full-scenario energy solutions, ensuring the benefits of technological progress are accessible across all mobility use cases.

Information Provided by PR Newswire [Disclaimer]
2026-04-21
21:48
Joyson Electronics Unveils First-ever Sustainability Dual Reports, Sets 2040 Core-Operations Net-Zero Target

HONG KONG and NINGBO, China, April 21, 2026 /PRNewswire/ -- Joyson Electronics (0699.HK) has, for the first time, released two sustainability-related reports in tandem—its Sustainability Report 2025 and Nature-related Disclosures Report 2025. It continues to embed sustainability into its strategy and long-term development.

During the year 2025, Joyson achieved solid progress across technology innovation, green manufacturing, and corporate social responsibility, and joined both the United Nations Global Compact (UNGC) and the Responsible Business Alliance (RBA)—helping drive the industry toward a greener and more prosperous future.

Riding the momentum of vehicle electrification and intelligent mobility, Joyson invested approximately RMB4.4 billion in forward-looking R&D in 2025. It remains committed to its "multi-chip platforms + ecosystem partnerships" technology roadmap, continuously advancing L3/L4 advanced driver assistance and autonomous driving capabilities, with multiple high-quality orders set to enter mass production starting 2026.

Beyond improving mobility efficiency and reducing emissions through intelligent technologies, Joyson Electronics also continues to roll out high-voltage, low-loss new energy management solutions, supporting greener mobility worldwide.

Basing on strong technology synergies, Joyson is further extending these capabilities into robotics components and server infrastructure, creating new growth engines. Joyson has launched a portfolio of products for robots, including central controllers, energy management and "limb" systems. And it is working with leading customers both in China and overseas.

In addition, Joyson has debuted an automotive optical module co-developed with Zhongji Innolight and is accelerating global commercialization of optical module technologies through investments that expand North American production capacity. Over the same period, the Company has also expanded its automotive-grade power electronics into industrial server power supply applications.

During the reporting period, Joyson Electronics used nearly 250,000 MWh of renewable energy—up 27% from 2024—avoiding over 100,000 tonnes of CO₂e emissions. Joyson is targeting carbon neutrality in core operations by 2040, and has also set goals—using 2024 as the baseline year—to strive for a 6% reduction in both water intensity and waste generation intensity by 2030.

Joyson stated that it will continue to fully integrate ESG into its strategy and operational management, further strengthening its ESG management system and creating a more prosperous and sustainable future for society.

About Joyson Electronics

Joyson Electronics (600699.SH / 699.HK) is a leading global provider of smart technology solutions, specializing in the R&D and manufacturing of automotive electronics, automotive safety systems, and key components for robots. Joyson operates more than 25 R&D centers and 60 production facilities, and serves over 100 global automotive brands. Revenue reached RMB 61.2 billion in 2025.

Joyson Electronics positions itself as a "Tier 1 supplier for automotive and robotics," providing customers with innovative products in the fields of autonomous driving, intelligent cockpits, car connectivity, E-Mobility, automotive safety, and key robotics components. It is a leading global supplier of autonomous driving, with its full-stack solutions supporting multi-scenario autonomous driving capabilities from Level 2 to Level 4. Joyson is also the second-largest supplier of intelligent cockpit domain control systems in China and the fourth largest globally.

Additionally, Joyson Electronics has supplied samples or products to robotics companies worldwide, establishing itself as a leader in the embodied intelligent robotics components industry.

 

Information Provided by PR Newswire [Disclaimer]
Subscribe Newsletter
Get the latest news from us by inputing your email address here.
(Please read our Privacy Policy)